Neoadjuvant Chemotherapy plus Interval Cytoreductive Surgery with or without Hyperthermic Intraperitoneal Chemotherapy (NIHIPEC) in the Treatment of Advanced Ovarian Cancer: A Multicentric Propensity Score Study.
Antoni LluecaMaria Victoria IbañezPedro CascalesAntonio Gil-MorenoVicente BebiaJordi Ponce SebastiàSergi FernandezArjona-Sánchez ÁlvaroJuan Carlos MuruzabalNadia Veiga CanutoBerta Díaz-FeijooCristina CeladaJuan Gilabert-EstellesCristina AghababyanJavier LacuevaAlicia CaleroJuan José Segura-SampedroKarina MaiocchiSara LlorcaAlvaro VillarinMaria Teresa Climent MartíKatty DelgadoAnna Serra RubertLuis Gomez-QuilesMaria Lluecanull On Behalf Of Spain Gog And Gecop Working GroupPublished in: Cancers (2023)
The addition of HIPEC after interval cytoreductive surgery is safe and increases DFS in advanced EOC patients.
Keyphrases
- neoadjuvant chemotherapy
- locally advanced
- minimally invasive
- coronary artery bypass
- end stage renal disease
- newly diagnosed
- ejection fraction
- lymph node
- chronic kidney disease
- sentinel lymph node
- rectal cancer
- surgical site infection
- squamous cell carcinoma
- radiation therapy
- early stage
- coronary artery disease
- acute coronary syndrome
- percutaneous coronary intervention
- combination therapy
- atrial fibrillation
- smoking cessation